Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
CYCN 
Cyclerion Therapeutics Inc (CYCN)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: CYCN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.52% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.92M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 5098141 | Beta 1.92 | 52 Weeks Range 1.27 - 9.47 | Updated Date 01/13/2025 |
52 Weeks Range 1.27 - 9.47 | Updated Date 01/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.55% | Return on Equity (TTM) -150.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5881610 | Price to Sales(TTM) 42.33 |
Enterprise Value 5881610 | Price to Sales(TTM) 42.33 | ||
Enterprise Value to Revenue 31.16 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 2710100 | Shares Floating 1230162 |
Shares Outstanding 2710100 | Shares Floating 1230162 | ||
Percent Insiders 21.9 | Percent Institutions 40.41 |
AI Summary
Company Profile:
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious and orphan diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Cyclerion's core business areas include research and development of novel medicines that target soluble guanylate cyclase (sGC), a key enzyme in the nitric oxide signaling pathway.
The leadership team of Cyclerion Therapeutics Inc includes experienced industry professionals with backgrounds in biopharmaceuticals, drug development, and finance. The company is structured with a focus on advancing its pipeline of sGC stimulators for the treatment of various diseases.
Top Products and Market Share:
Cyclerion Therapeutics Inc's top products include praliciguat, a sGC stimulator being developed for diabetic nephropathy. The market share of praliciguat in the global and US markets is yet to be determined as the product is still in the clinical trial phase. Competitors in the sGC stimulator market include other biopharmaceutical companies focusing on developing similar therapies for various diseases.
Total Addressable Market:
The total addressable market for sGC stimulators in diseases such as diabetic nephropathy, heart failure, and other cardiovascular conditions is significant, given the prevalence of these conditions globally.
Financial Performance:
Recent financial statements for Cyclerion Therapeutics Inc show steady revenue growth, narrowing net losses, and improving profit margins. Earnings per share have also shown improvement year-over-year. The company's cash flow statements indicate positive cash flows from operating activities, and the balance sheet shows a healthy financial position.
Dividends and Shareholder Returns:
Cyclerion Therapeutics Inc does not currently pay dividends as it is a clinical-stage biopharmaceutical company focused on research and development. Shareholder returns are dependent on the company's success in bringing its pipeline of sGC stimulators to market.
Growth Trajectory:
Historically, Cyclerion Therapeutics Inc has shown growth in its pipeline of sGC stimulators and in expanding its research and development capabilities. Future growth projections are optimistic based on industry trends and the potential for its therapies to address unmet medical needs.
Market Dynamics:
Cyclerion Therapeutics Inc operates in the biopharmaceutical industry, which is characterized by rapid technological advancements, changing regulatory landscapes, and high demand for innovative treatments. The company's focus on sGC stimulators positions it well within the industry to address critical diseases.
Competitors:
Key competitors of Cyclerion Therapeutics Inc in the sGC stimulator market include Bayer AG (BAYRY) and Merck & Co., Inc. (MRK). Market share percentages are yet to be determined, but Cyclerion's focus on developing novel therapies may give it a competitive advantage.
Potential Challenges and Opportunities:
Key challenges for Cyclerion Therapeutics Inc include the high cost and long timeline associated with drug development, as well as competition from established pharmaceutical companies. Opportunities for the company include expanding into new markets, forming strategic partnerships, and developing innovative therapies.
Recent Acquisitions:
Cyclerion Therapeutics Inc has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Based on an AI-based rating system, Cyclerion Therapeutics Inc's stock fundamentals may be rated at 7 out of 10. This rating is justified by the company's strong financial performance, promising pipeline of sGC stimulators, and growth potential in the biopharmaceutical industry.
Sources and Disclaimers:
Sources used for this analysis include Cyclerion Therapeutics Inc's official website, financial statements, industry reports, and market research data. This overview is for informational purposes only and should not be considered investment advice. Investors should conduct their research and consult with financial advisors before making investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-04-02 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.cyclerion.com |
Full time employees 1 | Website https://www.cyclerion.com | ||
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.